GlassScriptPhysician profile
Julianne Morton
NPI 1992070338
$4,126.81
in general payments reported to CMS, 2019-2025
25 companies · $690 in 2025
The $690 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $612 · 2020: $630 · 2021: $457 · 2022: $740 · 2023: $346 · 2024: $652 · 2025: $690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,678 · Education: $10.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,678.00 |
| Education | $10.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,714.54 | 2019-2025 | |
| Pfizer INC. | $483.32 | 2019-2025 | |
| Biogen, INC. | $269.23 | 2024-2025 | Zurzuvae |
| Allergan, INC. | $155.66 | 2019-2020 | |
| Avion Pharmaceuticals | $151.30 | 2020-2022 | |
| Exact Sciences Corporation | $150.70 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $149.25 | 2019-2024 | Gardasil 9, Gardasil, Vaqta |
| Roche Diagnostics Corporation | $145.18 | 2019 | |
| Organon LLC | $142.21 | 2022-2025 | Nexplanon, Jada System |
| Mylan Pharmaceuticals INC. | $132.00 | 2019-2020 | |
| Astellas Pharma US INC | $80.09 | 2024-2025 | Veozah |
| Exeltis, USA INC. | $79.66 | 2020-2025 | Slynd |
| Mayne Pharma Commercial LLC | $73.16 | 2022-2023 | |
| Therapeuticsmd, INC. | $72.96 | 2020-2021 | |
| Lupin INC. | $63.46 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $48.75 | 2025 | Flucelvax |
| Gynesonics, INC. | $44.02 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Dysis Medical, INC. | $36.05 | 2020-2022 | |
| Myovant Sciences INC. | $24.50 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.27 | 2025 | |
| Daiichi Sankyo INC. | $22.71 | 2022 | |
| Millicent US INC | $18.04 | 2024 | Femring, Intrarosa |
| Ferring Pharmaceuticals INC. | $17.64 | 2019 | |
| Boston Scientific Corporation | $14.54 | 2019 | |
| Becton, Dickinson and Company | $13.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julianne Morton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.